Fig. 4

PRIMA-1^MET and Noxa. a: Results of luciferase reporter assay. A significant increase in luciferase activity after PRIMA-1^MET treatment in Noxa wt and Noxa CREB but not Noxa p53 pGL10.4 plasmids. Dark grey: non-treated vehicle control. Light grey: PRIMA-1^MET treatment (24 h, 15 μM). NOXA wt: pGL10.4 plasmid with normal Noxa promoter sequence. Noxa p53: pGL10.4 plasmid with Noxa promoter sequence containing mutation at the p53 binding site. Noxa CREB: pGL10.4 plasmid with Noxa promoter sequence containing mutation at the CREB binding site. b: Sensitization of SK-N-SH cells by pretreatment with orlistat. Dark grey: non-treated vehicle control. Light grey: PRIMA-1^MET treatment (24 h, 10 μM). Left columns: orlistat non-treated vehicle control. Right columns: orlistat treatment (5 μM, 6 h prior to PRIMA-1^MET treatment). c: Impact of pan-caspase inhibitor on the growth curve of SK-N-SH cells. Red lines: cells treated with pan-caspase inhibitor (22 h, 50 μM). Blue lines: Non-treated vehicle controls. Full line: non-treated vehicle control for PRIMA-1^MET. Dotted line: PRIMA-1^MET treated cell line (22 h, 20 μM). Dashed line: etoposide treatment (22 h, 30 μM)